【摘要】 目的评估1 550nm铒玻璃点阵激光治疗中重度痤疮的临床疗效和安全性。方法采用1 550nm铒玻璃点阵激光治疗16例中重度痤疮患者。使用点阵密度169点/cm2,能量密度10mJ/cm2,首先对活动性皮损照射一遍,然后对整个面部照射一遍,共治疗4次,每次间隔2周。治疗结束后6个月时再抽取其中8例患者进行对照研究,仅对其中有4例接受1次附加治疗,3个月后进行最终疗效评估。结果有13例患者完成了治疗和随访。治疗结束后6个月时患者评价Burton痤疮评分的平均改善率为68.12%,观察者为81.36%,未使用麻醉药物,未出现不良反应。接受附加1次治疗后的3个月时,接受1次附加治疗组患者评价Burton痤疮评分的平均改善率为80.65%,观察者为84.37%,明显高于未接受附加治疗的患者(68.04%和75.31%),前者明显优于后者,差异均有统计学意义(P均<0.05)。结论 1 550nm铒玻璃点阵激光治疗面部炎性痤疮疗效好,疼痛轻微且无不良反应,增加其维持治疗次数可提高临床疗效。更多还原

【Abstract】 Objective To evaluate the effect of the 1 550-nm erbium: glass fractional laser in the treatment of moderate to severe inflammatory acne on the face. Methods Sixteen patients with moderate to severe acne were treated with the 1 550 nm erbium: glass fractional laser( Sellas-Evo,Korea) at 169 spots /cm2 and 10mJ /cm2for4 times at 2-week intervals. Active lesions were treated before the entire face each time. 8 patients continued in a double-arm study to determine whether an additional treatment at 6 months would prolong the lesion-free period. Final evaluation was at 9 months. Results Thirteen patients completed the study. At 6-month follow-up,patients rated improvement as 68. 12%,and the mean investigator improvement assessment was81. 36%. No patients required anesthesia,and no side effects were observed. A single retreatment session after the treatment course held patients improvement assessment as 80. 65% and investigator improvement assessment as 84. 37% at 3-month follow-up,whereas patients without retreatment had 68. 04% and 75. 31%improvement. The effect of former group was significantly superior to the latter( P < 0. 05). Conclusion Treatment of inflammatory facial acne with the 1 550-nm erbium: glass fractional laser is effective and relatively painless without side effect. Additional treatment sessions may prolong the lesion-free period.更多还原